Aromatase inhibitors and xenograft studies

Steroids

Volumn 76, Issue 8, 2011, Pages 730-735

  Chumsri, Saranya ^a   Sabnis, Gauri J ^a   Howes, Timothy ^a   Brodie, Angela M H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase Inhibitor Breast Cancer Xenograft and Models

Indexed keywords

AROMATASE; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; HISTONE; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE 1; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONFERENCE PAPER; CONTROLLED STUDY; DEACETYLATION; DRUG POTENTIATION; ENZYME ACTIVATION; EPIGENETICS; FEMALE; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; AROMATASE INHIBITORS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PHOSPHORYLATION; PYRIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958766981     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.033     Document Type: Conference Paper

References (32)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
2. The American Cancer Society A, Georgia. Breast cancer facts & figures 2009-2010; 2009-2010.
3. Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Molecular cancer therapeutics 2010;9:46-56.
4. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009;69:1416-28.
5. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007;13:2751-7. (Pubitemid 46788044)
6. Sabnis GJ, Macedo L, Goloubeva O, Schayowitz A, Zhu Y, Brodie A. Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol 2008;108:1-7. (Pubitemid 351173816)
7. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008;68:4518-24.
8. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005;65:5380-9. (Pubitemid 40834290)
9. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10. (Pubitemid 40616372)
10. Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998;67:293-304. (Pubitemid 28559227)
11. Kazi AA, Jones JM, Koos RD. Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 2005;19:2006-19. (Pubitemid 41130691)
12. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44. (Pubitemid 40827357)
13. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
14. Joel PB, Traish AM, Lannigan DA. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998;273:13317-23. (Pubitemid 28246906)
15. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21:4921-31.
16. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
17. Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-63. (Pubitemid 40993251)
18. Lipton A, Ali S, Leitzel K. HER-2 protein expression predicts response to trastuzumab in FISH-positive patients with metastatic breast cancer. In: 31st AACR-CTRC San Antonio breast cancer symposium 2008, San Antonio, TX. 2008.
19. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9. (Pubitemid 46294957)
20. Mackey J, Kaufman B, Clemens M. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl. 1) (abstract 3).
21. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
22. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
23. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7. (Pubitemid 30185917)
24. Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 1999;84:203-8. (Pubitemid 29256742)
25. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5. (Pubitemid 24173735)
26. Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 1998;58:2515-9. (Pubitemid 28275417)
27. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55: 2279-83.
28. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-9. (Pubitemid 32946489)
29. Sabnis G, Goloubeva O, Macedo L, Gediya L, Njar V, Brodie A. Combination of HDACi entinostat (SNDX-275) with letrozole in provides superior control over tumor growth in MDA-MB-231 xenograft model. In: The 31st, annual San Antonio breast cancer symposium, 2008, San Antonio, TX. 2008.
30. Sabnis G, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie A. Functional activation of the estrogen receptor-( and aromatase by the HDAC inhibitor, entinostat, sensitizes of ER-negative tumors to letrozole. Cancer Res 2010;71:1893-903.
31. Azuma K, Urano T, Horie-Inoue K, et al. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009;69:2935-40.
32. Chen S, Ye J, Kijima I, Evans D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci USA 2010;107:11032-7.